
Alghad
HealthJordan22 Nov 2026, 11:08
New Vaccine Prevents Malaria Infection by 87%
Machine translated | Original title: لقاح جديد يقي من عدوى الملاريا بنسبة 87 %
The short version
Clinical trial results showed that a new experimental malaria vaccine achieved an 87 percent efficacy rate in preventing infection.
The full story
Recent clinical trial results revealed that a new experimental malaria vaccine achieved an efficacy rate of eighty-seven percent in preventing infection. The vaccine, designated as "PfSPZ-LARC2," was tested by intentionally exposing participants to live malaria parasites in a controlled environment. These findings were presented during the annual meeting of the American Society of Tropical Medicine and Hygiene held in Washington.
The vaccine's mechanism relies on live parasites that have been genetically attenuated to prevent them from completing their growth cycle within the human liver, enabling the immune system to recognize them and build a strong defense. Tests showed that only two out of fifteen individuals who received the vaccine became infected, compared to all seven participants in the placebo group after both groups were exposed to live parasites. All infected individuals received safe and prompt treatment, while the vaccine demonstrated good safety and tolerability.
The significance of these findings lies in the vaccine's ability to provide protection despite the strain used in testing differing from the one used in its development, a major challenge given the geographical diversity of the parasites responsible for thousands of annual global deaths, particularly in sub-Saharan Africa.
Malaria is a parasitic disease transmitted by female Anopheles mosquitoes, attacking the liver and red blood cells and causing symptoms that can escalate to severe and life-threatening complications for vulnerable groups such as children and pregnant women. This advancement represents the culmination of decades of research and genetic engineering to develop effective preventive solutions.
Source: Alghad
Read the full story at the sourceAsk Fahim about this story
Fahim answers from this story and, when it is not there, searches the web and keeps that part separate. No opinions.
Automated answers from the story text; they can be wrong. Check the source.




Comments
Comments are checked automatically. No abuse, links or phone numbers.